3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Melanoma
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Docetaxel
35
pembrolizumab
32
Nivolumab
27
enzalutamide
20
Prednisone
20
Sunitinib
16
Cyclophosphamide
16
aldesleukin
14
Zoledronic Acid
13
Interleukin-2
13
Gemcitabine
13
Bevacizumab
13
Specimen Handling
12
Ipilimumab
12
Radiosurgery
11
Everolimus
11
Androgen Antagonists
11
Abiraterone Acetate
11
fludarabine
10
Sorafenib
10
Radiotherapy
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
pazopanib
9
abiraterone
9
Doxorubicin
8
Carboplatin
8
Biopsy
8
avelumab
7
temsirolimus
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Interleukin-15
×
Genitourinary
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled